Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?
Figure 1
Hazard ratio of chronic heart failure (CHF), acute myocardial infarction (AMI) and all cause mortality for use of TZDs versus other oral hypoglycemic drugs (95% CI). This figure shows the association of TZDs with CHF, AMI and mortality, compared with other oral hypoglycemic agents; ; [19].
